The three Sopharma AD factories - the one in Kazanlak, the Tablet production and Ampoule production in Sofia - have Nivalin in common, one of the strongest Sopharma products. Nivalin is sold in more than 10 countries outside Bulgaria, making it one of the most famous Sopharma products. It increases the intensity of the reflex centers of the spinal cord, medulla oblongata and cerebral cortex, thus influences all links of the reflex arc.
Sofia, Bulgaria, October 7, 2019 - Sopharma AD notifies that for September 2019 the Company recorded an increase in sales of 31% compared to the same month of 2018, incl. 5% decrease in sales for the domestic market and 66% increase in export sales.
In the first nine months of 2019 the revenues from sales of production increased by 2% compared to the same period of 2018, incl. 9% decrease in domestic sales and 10% increase in export sales.
Sofia, Bulgaria, September 27, 2019 - Sopharma AD (3JR: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that on September 26, 2019 the Company bought 182 own shares representing 0.0001% of the share capital of the Company, at a total value of 607.88 BGN on the Bulgarian Stock Exchange, the average price per share was 3.34 BGN.
The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.
